ChemicalBook > CAS DataBase List > Nurulimab
Nurulimab
- Product Name
- Nurulimab
- CAS No.
- 2168561-20-2
- Chemical Name
- Nurulimab
- Synonyms
- Nurulimab;Nurulimab (anti-CTLA-4);Research Grade Nurulimab;Research Grade Nurulimab(DHD17205)
- CBNumber
- CB48081180
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Nurulimab Property
- form
- Liquid
- color
- Colorless to light yellow
More
Less
Nurulimab Chemical Properties,Usage,Production
Uses
Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma[1].
References
[1] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 34, No. 1, 2020.
Nurulimab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Nurulimab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
2168561-20-2, NurulimabRelated Search:
Balstilimab
Enokizumab
Batoclimab
Brodalumab
Inebilizumab
Mavrilimumab
Varisacumab
Denosumab
Elezanumab
Crotedumab